Literature DB >> 18632251

Genes required for functional glycosylation of dystroglycan are conserved in zebrafish.

Christopher J Moore1, Huey Tse Goh, Jane E Hewitt.   

Abstract

Mutations in human genes encoding proteins involved in alpha-dystroglycan glycosylation result in dystroglycanopathies: severe congenital muscular dystrophy phenotypes often accompanied by CNS abnormalities and ocular defects. We have identified the zebrafish orthologues of the seven known genes in this pathway and examined their expression during embryonic development. Zebrafish Large, POMT1, POMT2, POMGnT1, Fukutin, and FKRP show in situ hybridization patterns similar to those of dystroglycan, with broad expression throughout early development. By 30 h postfertilization (hpf), transcripts of all these genes are most prominent in the CNS, eye, and muscle, tissues that are predominantly affected in the dystroglycanopathies. In contrast, Large2 expression is more restricted and by 30 hpf is confined to the lens, cerebellum, and pronephric duct. We show that the monoclonal antibody IIH6, which recognizes a glycoform of dystroglycan, also detects the zebrafish protein. Injection of morpholino oligonucleotides against zebrafish Large2 resulted in loss of IIH6 immunostaining. These data indicate that the dystroglycan glycosylation pathway is conserved in zebrafish and suggest this organism is likely to be a useful model system for functional studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632251     DOI: 10.1016/j.ygeno.2008.05.008

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  16 in total

1.  Drug screening in a zebrafish model of Duchenne muscular dystrophy.

Authors:  Genri Kawahara; Jeremy A Karpf; Jennifer A Myers; Matthew S Alexander; Jeffrey R Guyon; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

2.  A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Authors:  Peter R Serafini; Michael J Feyder; Rylie M Hightower; Daniela Garcia-Perez; Natássia M Vieira; Angela Lek; Devin E Gibbs; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel; Matthew S Alexander
Journal:  JCI Insight       Date:  2018-09-20

Review 3.  The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy.

Authors:  Lance Wells
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

Review 4.  Swimming into prominence: the zebrafish as a valuable tool for studying human myopathies and muscular dystrophies.

Authors:  Elizabeth M Gibbs; Eric J Horstick; James J Dowling
Journal:  FEBS J       Date:  2013-07-25       Impact factor: 5.542

Review 5.  Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes.

Authors:  Naosuke Nakamura; Dmitry Lyalin; Vladislav M Panin
Journal:  Semin Cell Dev Biol       Date:  2010-04-01       Impact factor: 7.727

Review 6.  Recent advancements in understanding mammalian O-mannosylation.

Authors:  M Osman Sheikh; Stephanie M Halmo; Lance Wells
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

Review 7.  "Casting" light on the role of glycosylation during embryonic development: insights from zebrafish.

Authors:  Heather R Flanagan-Steet; Richard Steet
Journal:  Glycoconj J       Date:  2012-05-26       Impact factor: 2.916

Review 8.  Dystroglycan glycosylation and muscular dystrophy.

Authors:  Christopher J Moore; Jane E Hewitt
Journal:  Glycoconj J       Date:  2008-09-05       Impact factor: 2.916

9.  Zebrafish based small molecule screens for novel DMD drugs.

Authors:  Genri Kawahara; Louis M Kunkel
Journal:  Drug Discov Today Technol       Date:  2013

10.  Zebrafish models for human FKRP muscular dystrophies.

Authors:  Genri Kawahara; Jeffrey R Guyon; Yukio Nakamura; Louis M Kunkel
Journal:  Hum Mol Genet       Date:  2009-12-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.